The influence of pathological mutations and proline substitutions in TDP-43 glycine-rich peptides on its amyloid properties and cellular toxicity

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Sun, Chia Sui ^a,b,c   Wang, Cindy Yu Hsiang ^b,d   Chen, Bryan Po Wen ^b   He, Ruei Yu ^b   Liu, Gerard Chun Hao ^b,d   Wang, Chih Hsien ^e   Chen, Wenlung ^e   Chern, Yijuang ^c   Huang, Joseph Jen Tse ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF CHEMISTRY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE; LIPOSOME; PROLINE; TAR DNA BINDING PROTEIN; THIOFLAVINE; AMYLOID; DNA BINDING PROTEIN; MUTANT PROTEIN; PEPTIDE; PROTEIN AGGREGATE; PROTEIN TDP-43; THIAZOLE DERIVATIVE;

AMINO ACID SUBSTITUTION; AMYLOIDOSIS; ANIMAL CELL; ARTICLE; ASSAY; BETA SHEET; CALCEIN LEAKAGE ASSAY; CARBOXY TERMINAL SEQUENCE; CELL SURVIVAL; CELL VIABILITY ASSAY; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; MOUSE; MUTATION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN STRUCTURE; RAMAN SPECTROMETRY; THIOFLAVIN T ASSAY; TRANSMISSION ELECTRON MICROSCOPY; AMINO ACID SEQUENCE; ANIMAL; CELL MEMBRANE; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR GENETICS; PROTEIN MULTIMERIZATION; PROTEIN SECONDARY STRUCTURE; TIME; ULTRASTRUCTURE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMYLOID; ANIMALS; CELL MEMBRANE; DNA-BINDING PROTEINS; GLYCINE; MICE; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; MUTATION; PEPTIDES; PROLINE; PROTEIN AGGREGATES; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; SPECTRUM ANALYSIS, RAMAN; THIAZOLES; TIME FACTORS;

EID: 84905493040     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103644     Document Type: Article

References (48)

1. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130-133. (Pubitemid 44547757)
2. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, et al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351: 602-611. (Pubitemid 44708852)
3. Jiang LL, Che MX, Zhao J, Zhou CJ, Xie MY, et al. (2013) Structural Transformation of the Amyloidogenic Core Region of TAR DNA Binding Protein of 43 kDa (TDP-43) Initiates Its Aggregation and Cytoplasmic Inclusion. J Biol Chem 288: 19614-19624.
4. Parker SJ, Meyerowitz J, James JL, Liddell JR, Crouch PJ, et al. (2012) Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem Int 60: 415-424.
5. Gendron TF, Josephs KA, Petrucelli L (2010) Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. Neuropathol Appl Neurobiol 36: 97-112.
6. Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, et al. (2010) Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One 5: e13250.
7. Chang CK, Wu TH, Wu CY, Chiang MH, Toh EK, et al. (2012) The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem Biophys Res Commun 425: 219-224.
8. Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL (2008) Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol 67: 1159-1165.
9. Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, et al. (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67: 555-564. (Pubitemid 351787082)
10. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, et al. (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 61: 435-445. (Pubitemid 46878771)
11. Gendron TF, Rademakers R, Petrucelli L (2013) TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. J Alzheimers Dis 33 Suppl 1: S35-45.
12. Pesiridis GS, Lee VM, Trojanowski JQ (2009) Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet 18: R156-162.
13. Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, et al. (2009) TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 284: 20329- 20339.
14. Xu YF, Zhang YJ, Lin WL, Cao X, Stetler C, et al. (2011) Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol Neurodegener 6: 73.
15. Janssens J, Van Broeckhoven C (2013) Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum Mol Genet 22: R77-87.
16. Zhou H, Huang C, Chen H, Wang D, Landel CP, et al. (2010) Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS genetics 6: e1000887.
17. Guo W, Chen Y, Zhou X, Kar A, Ray P, et al. (2011) An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat Struct Mol Biol 18: 822-830.
18. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH (2009) TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 106: 18809-18814.
19. Liu GC, Chen BP, Ye NT, Wang CH, Chen W, et al. (2013) Delineating the membrane-disrupting and seeding properties of the TDP-43 amyloidogenic core. Chemical communications 49: 11212-11214.
20. Chen AK, Lin RY, Hsieh EZ, Tu PH, Chen RP, et al. (2010) Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J Am Chem Soc 132: 1186-1187.
21. Blanch EW, Morozova-Roche LA, Cochran DA, Doig AJ, Hecht L, et al. (2000) Is polyproline II helix the killer conformation? A Raman optical activity study of the amyloidogenic prefibrillar intermediate of human lysozyme. J Mol Biol 301: 553-563.
22. Darnell G, Orgel JP, Pahl R, Meredith SC (2007) Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. J Mol Biol 374: 688-704. (Pubitemid 350027728)
23. Chou PY, Fasman GD (1978) Empirical predictions of protein conformation. Annu Rev Biochem 47: 251-276.
24. King OD, Gitler AD, Shorter J (2012) The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res 1462: 61-80.
25. Polymenidou M, Cleveland DW (2011) The seeds of neurodegeneration: prionlike spreading in ALS. Cell 147: 498-508.
26. Cushman M, Johnson BS, King OD, Gitler AD, Shorter J (2010) Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci 123: 1191-1201.
27. Bigio EH, Wu JY, Deng HX, Bit-Ivan EN, Mao Q, et al. (2013) Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol 125: 463-465.
28. Robinson JL, Geser F, Stieber A, Umoh M, Kwong LK, et al. (2013) TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol 125: 121-131.
29. Saini A, Chauhan VS (2011) Delineation of the core aggregation sequences of TDP-43 C-terminal fragment. Chembiochem 12: 2495-2501.
30. Quist A, Doudevski I, Lin H, Azimova R, Ng D, et al. (2005) Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A 102: 10427-10432. (Pubitemid 41061570)
31. Narayan P, Ganzinger KA, McColl J, Weimann L, Meehan S, et al. (2013) Single molecule characterization of the interactions between amyloid-beta peptides and the membranes of hippocampal cells. J Am Chem Soc 135: 1491-1498.
32. Lin H, Bhatia R, Lal R (2001) Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. Faseb J 15: 2433-2444. (Pubitemid 33063171)
33. Malchiodi-Albedi F, Paradisi S, Matteucci A, Frank C, Diociaiuti M (2011) Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts. Int J Alzheimers Dis 2011: 906964.
34. Arispe N, Rojas E, Pollard HB (1993) Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A 90: 567-571. (Pubitemid 23028904)
35. Wang IF, Chang HY, Hou SC, Liou GG, Way TD, et al. (2012) The self-interaction of native TDP-43 C terminus inhibits its degradation and contributes to early proteinopathies. Nat Commun 3: 766.
36. He Y, Smith R (2009) Nuclear functions of heterogeneous nuclear ribonucleo-proteins A/B. Cellular and molecular life sciences: CMLS 66: 1239-1256.
37. Udan M, Baloh RH (2011) Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion 5: 1-5.
38. Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, et al. (2005) TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem 280: 37572-37584. (Pubitemid 41642366)
39. D'Ambrogio A, Buratti E, Stuani C, Guarnaccia C, Romano M, et al. (2009) Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res 37: 4116-4126.
40. Jiang P, Xu W, Mu Y (2009) Amyloidogenesis abolished by proline substitutions but enhanced by lipid binding. PLoS Comput Biol 5: e1000357.
41. Morimoto A, Irie K, Murakami K, Masuda Y, Ohigashi H, et al. (2004) Analysis of the secondary structure of beta-amyloid (Abeta42) fibrils by systematic proline replacement. J Biol Chem 279: 52781-52788. (Pubitemid 39656654)
42. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, et al. (1998) Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 4: 822-826. (Pubitemid 28331024)
43. Abedini A, Meng F, Raleigh DP (2007) A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor. J Am Chem Soc 129: 11300-11301. (Pubitemid 47555526)
44. Soto C, Kindy MS, Baumann M, Frangione B (1996) Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun 226: 672-680. (Pubitemid 26348532)
45. Poduslo JF, Curran GL, Kumar A, Frangione B, Soto C (1999) Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol 39: 371-382. (Pubitemid 29239200)
46. Thakur AK, Wetzel R (2002) Mutational analysis of the structural organization of polyglutamine aggregates. Proc Natl Acad Sci U S A 99: 17014-17019. (Pubitemid 36034090)
47. Wigley WC, Corboy MJ, Cutler TD, Thibodeau PH, Oldan J, et al. (2002) A protein sequence that can encode native structure by disfavoring alternate conformations. Nat Struct Biol 9: 381-388. (Pubitemid 34462558)
48. Wood SJ, Wetzel R, Martin JD, Hurle MR (1995) Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochemistry 34: 724-730.